

Impact of Institutional Monthly Volume of Transcatheter Edge-to-Edge Repair Procedures for Significant Mitral Regurgitation: Evidence from the GIOTTO-VAT Study

Nicola Corcione , Paolo Ferraro , [Filippo Finizio](#) , [Michele Cimmino](#) , Michele Albanese , Alberto Morello , [Giuseppe Biondi-Zoccai](#) ^{*} , [Paolo Dentì](#) , Antonio Popolo Rubbio , [Francesco Bedogni](#) , [Antonio Bartorelli](#) , Annalisa Mongiardo , [Salvatore Giordano](#) , Francesco De Felice , Marianna Adamo , [Matteo Montorfano](#) , [Francesco Maisano](#) , [Giuseppe Tarantini](#) , Francesco Giannini , [Federico Ronco](#) , [Emmanuel Villa](#) , Maurizio Ferrario , Luigi Fiocca , [Fausto Castriota](#) , [Angelo Squeri](#) , [Martino Pepe](#) , Corrado Tamburino , Arturo Giordano

Posted Date: 27 March 2025

doi: 10.20944/preprints202503.2077.v1

Keywords: caseload; experience; mitral regurgitation; mitralclip; volume



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Impact of Institutional Monthly Volume of Transcatheter Edge-to-Edge Repair Procedures for Significant Mitral Regurgitation: Evidence from the GIOTTO-VAT Study

Running title: The GIOTTO-VAT study

Nicola Corcione ¹, Paolo Ferraro ², Filippo Finizio ¹, Michele Cimmino ¹, Michele Albanese ², Alberto Morello ¹, Giuseppe Biondi-Zoccai ^{3,4,*}, Paolo Denti ⁵, Antonio Popolo Rubbio ⁶, Francesco Bedogni ⁶, Antonio L. Bartorelli ⁷, Annalisa Mongiardo ⁸, Salvatore Giordano ⁸, Francesco De Felice ⁹, Marianna Adamo ¹⁰, Matteo Montorfano ¹¹, Francesco Maisano ¹¹, Giuseppe Tarantini ¹², Francesco Giannini ¹³, Federico Ronco ¹⁴, Emmanuel Villa ¹⁵, Maurizio Ferrario ¹⁶, Luigi Fiocca ¹⁷, Fausto Castriota ¹⁸, Angelo Squeri ¹⁸, Martino Pepe ¹⁹, Corrado Tamburino ²⁰ and Arturo Giordano ¹

¹ Unità Operativa di Interventistica Cardiovascolare, Pineta Grande Hospital, Castel Volturno, Italy;

² Unità Operativa di Emodinamica, Santa Lucia Hospital, San Giuseppe Vesuviano, Italy

³ Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

⁴ Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy

⁵ Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, +Italy

⁶ Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy

⁷ IRCCS Ospedale Galeazzi-Sant' Ambrogio, Milan, Italy, and Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

⁸ Division of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University

⁹ Division of Interventional Cardiology, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy

¹⁰ Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health University of Brescia, both in Brescia, Italy

¹¹ School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹² Department of Cardiac, Thoracic and Vascular Science, Interventional Cardiology Unit, University of Padua, Padua, Italy

¹³ Division of Cardiology, IRCCS Ospedale Galeazzi - Sant' Ambrogio, Milan, Italy

¹⁴ Interventional Cardiology, Department of Cardio-Thoracic and Vascular Sciences, Ospedale dell' Angelo, AULSS3 Serenissima, Mestre, Venezia, Italy

¹⁵ Cardiac Surgery Unit and Valve Center, Poliambulanza Foundation Hospital, Brescia, Italy

¹⁶ Division of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

¹⁷ Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy

¹⁸ Interventional Cardiology Unit, GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy

¹⁹ Division of Cardiology, Department of Interdisciplinary Medicine (D.I.M.), University of Bari Aldo Moro, Bari, Italy

²⁰ Division of Cardiology, Centro Alte Specialità e Trapianti (CAST), Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy

* Correspondence: giuseppe.biondizoccai@uniroma1.it

Abstract: Background: Mitral valve transcatheter edge-to-edge repair (TEER) is a widely adopted therapeutic approach for managing significant mitral regurgitation (MR) in high-risk surgical candidates. While procedural safety and efficacy have been demonstrated, the impact of institutional

expertise on outcomes remains unclear. We aimed at evaluating whether institutional monthly volume of TEER influences short- and long-term clinical results. **Methods:** This analysis from the multicenter, prospective GIOTTO trial study evaluated the impact of institutional monthly volume on outcomes of TEER for significant mitral regurgitation. Centers were stratified into tertiles based on monthly volumes (≤ 2.0 cases/month, 2.1-3.5 cases/month, > 3.5 cases/month), and key clinical, echocardiographic, and procedural outcomes were analyzed. Statistical analysis was based on standard bivariate tests as well as unadjusted and multivariable adjusted Cox models. **Results:** A total of 2,213 patients were included, stratified into tertiles based on institutional procedural volume: 645 (29.1%) patients in the first tertile, 947 (42.8%) patients in the second tertile, and 621 (28.1%) patients in the third tertile. Several baseline differences were found, with some features disfavoring less busy centers (eg functional class and surgical risk, both $p < 0.05$), and others suggesting a worse risk profile in those treated in busier institutions (eg frailty and history of prior mitral valve intervention, both $p < 0.05$). Procedural success rates were higher in busier centers ($p < 0.001$), and hospital stay was also shorter there ($p < 0.001$). Long-term follow-up (median 14 months) suggested worse outcomes in patients treated in less busy centers at unadjusted analysis (eg $p = 0.018$ for death, $p = 0.015$ for cardiac death, $p = 0.014$ for death or hospitalization for heart failure, $p < 0.001$ for cardiac death or hospitalization for heart failure), even if these associations proved no longer significant after multivariable adjustment, except for cardiac death or hospitalization for heart failure, which appeared significantly less common in the busiest centers ($p < 0.05$). Similar trends were observed when focusing on tertiles of overall center volume and when comparing for each center the first 50 cases with the following ones. **Conclusion:** High institutional monthly volume in TEER mitral valve repair appears to correlate with improved procedural success rate and shorter hospitalizations. Similarly favorable results were found for long-term rates of cardiac death or hospitalization for heart failure. These findings inform on the importance of operator experience and center expertise to achieve state-of-the-art results with TEER, while confirming the usefulness of the proctoring approach when naïve centers begin a TEER program.

Keywords: Caseload; experience; mitral regurgitation; Mitraclip; volume

Introduction

Transcatheter edge-to-edge repair (TEER) has emerged as an effective alternative to surgical valve repair in high-risk patients, and to conservative medical therapy only in carefully selected individuals considered unfit for surgery.(1-2) Indeed, given its ability to improve functional outcomes and reduce heart failure hospitalizations, TEER is increasingly performed worldwide.(3) However, the early and long-term effectiveness of TEER is impacted by several factors, ranging from patient to anatomic and procedural ones.(4-13)

On top of patient, procedural and operator features, institutional characteristics have been the focus of attentive recommendations and analysis.(14) Indeed, in most settings TEER is only provided as long as surgical mitral valve repair/replacement is also available. Yet, this minimum requirement might be too lenient, as long as expertise in patient screening and selection, procedural efficiency and seamless quality of care are paramount to achieve optimal outcomes with TEER.(15) In particular, a number of cut-offs have been proposed and tested formally in the past, under the key premise that higher volume centers may provide better results, shortly after the procedure as well as subsequently. However, results have been inconsistent so far, with some studies suggesting that no evident cut-off can be envisioned, and others ending up recommending a minimum yearly volume ranging from 8 to 24 cases.(16-18)

We have previously leveraged the extensive and detailed dataset of the ongoing prospective GIOTTO (GIse registry Of Transcatheter treatment of mitral valve regurgitaTiOn) registry, an Italian multicenter observational study including patients undergoing TEER with MitraClip (Abbott

Vascular, Santa Clara, CA, USA), for inferential purposes.(5,19-20) We hereby aimed at conducting an analysis explicitly dedicated to investigate the impact of institutional TEER volume on clinical outcomes in patients undergoing transcatheter mitral valve repair with the MitraClip device. Key strengths of GIOTTO include its contemporary stance and follow-up which goes well beyond discharge. The key underlying hypothesis of this study was that higher volume/time centers could provide better care for patients undergoing TEER than institutions characterized by fewer procedures over time.

Methods

This study was based on the dataset accrued in the GIOTTO trial, which is sponsored by the Italian Society of Invasive Cardiology (GISE - Società Italiana di Cardiologia Interventistica, Milan, Italy) and is registered online in ClinicalTrials.gov (NCT03521921).(5) Notably, ethical approval was obtained from all participating institutions, and all patients provided written informed consent.

For the purpose of this analysis, which we labelled GIOTTO-VAT (Volume And Time), we mainly focused on comparing tertiles of cases per month, center-wise, with the first tertile up to 2.0 cases per month, the second tertile with more than 2.0 and up to 3.5 cases per month, and the third tertile with more than 3.5 cases per month. Exploratory analyses were conducted according to tertiles of total volume, center-wise, with the first tertile up to 100 cases, the second tertile with more than 100 and up to 200 cases, and the third tertile with more than 200 cases, as well as distinguishing between the first 50 cases per center and the subsequent ones.

Details on baseline variables were collected, including demographic data, comorbidities, functional class, prior cardiac procedures, and medication history. Echocardiographic parameters being assessed included left atrial diameter, left ventricular dimensions, mitral valve gradient, and severity of tricuspid regurgitation. Procedural variables of interest included number and generation of MitraClip devices implanted, fluoroscopy time, device time, and procedural success. Fatal and non-fatal outcomes occurring during the index hospitalization and during follow-up were systematically collected, with specific attention to the following events: death, cardiac death, the composite of death or hospitalization, and the composite of death or hospitalization for heart failure

Descriptive statistics were computed for all variables, with medians, 1st and 3rd quartiles provided for continuous variables and counts and percentages for categorical variables. Bivariate analysis was based on Kruskal-Wallis tests for continuous variables and Fisher exact tests for categorical variables. Censored outcomes were analyzed with Cox proportional hazard models, unadjusted as well as adjusted for potential confounders. No missing data imputation was performed. Statistical significance was set at a 2-tailed p-value of 0.05, without multiplicity adjustments, and all analyses were conducted using Stata 18 (StataCorp, College Station, TX, USA).

Results

A total of 2,213 patients were included, with 645 (29.1%) individuals treated in centers performing ≤2.0 cases/month, 947 (42.8%) treated in institutions reporting between 2.1 and 3.5 cases/month, 621 (28.1%) patients treated in hospitals with >3.5 cases/month (Table 1). Several differences according to such stratifications were found in key baseline features, with some suggesting a higher complexity in patients treated in lower volume centers, such as age, functional class, and surgical risk score (all p<0.05), and others suggesting a higher risk in those treated in busier centers, such as smoking, dyslipidemia, prior mitral valve intervention, prior stroke, peripheral artery disease, and frailty score (all p<0.05).

Table 1. Baseline clinical features according to tertiles of monthly volume, center-wise.*.

Feature	First tertile	Second tertile	Third tertile	P
Patients	645	947	621	-

Age (years)	78 (72; 83)	77 (70; 82)	79 (70; 83)	<0.001
Female gender	211 (32.7%)	586 (61.9%)	380 (61.2%)	0.039
Body mass index	24.9 (22.7; 27.6)	24.8 (22.1; 27.8)	23.4 (2.0; 25.6)	0.356
Smoking history	72 (11.1%)	88 (9.3%)	163 (26.3%)	<0.001
Hypertension	462 (71.6%)	696 (73.5%)	445 (71.7%)	0.628
Dyslipidemia	212 (32.9%)	256 (27.0%)	267 (43.0%)	<0.001
Diabetes mellitus	157 (24.3%)	220 (23.2%)	144 (23.2%)	0.851
Diagnosis				0.002
Degenerative MR	176 (27.3%)	330 (34.9%)	198 (31.9%)	
Functional dilated MR	199 (30.9%)	277 (29.3%)	180 (29.0%)	
Functional ischemic MR	194 (30.1%)	230 (24.3%)	194 (31.2%)	
Mixed etiology	76 (11.8%)	110 (11.6%)	49 (7.9%)	
New York Association class				<0.001
I	4 (0.6%)	11 (1.2%)	17 (2.8%)	
II	110 (17.1%)	215 (22.7%)	196 (31.9%)	
III	452 (70.1%)	660 (69.7%)	350 (57.0%)	
IV	79 (12.3%)	61 (6.4%)	51 (8.3%)	
Coronary artery disease				0.711
None	201 (63.8%)	134 (60.1%)	275 (64.0%)	
Single vessel disease	49 (15.6%)	42 (18.8%)	67 (15.6%)	
Two vessel disease	25 (7.9%)	23 (10.3%)	48 (11.2%)	
Three vessel disease	22 (7.0%)	13 (5.8%)	22 (5.1%)	
Left main disease	18 (5.7%)	11 (4.9%)	18 (4.2%)	
Prior pacemaker implantation				
Prior myocardial infarction	213 (33.0%)	312 (33.0%)	194 (31.2%)	0.735
Prior coronary artery bypass grafting	83 (12.9%)	126 (13.3%)	104 (16.8%)	0.087
Prior mitral valve intervention	17 (2.6%)	14 (1.5%)	38 (6.1%)	<0.001
Prior cerebrovascular event				<0.001
None	601 (93.2%)	891 (94.1%)	548 (88.2%)	
Transient ischemic attack	12 (1.9%)	14 (1.5%)	31 (5.0%)	
Minor stroke	17 (2.6%)	22 (2.3%)	12 (1.9%)	
Major stroke	15 (2.3%)	20 (2.1%)	30 (4.8%)	
Peripheral artery disease	54 (8.4%)	38 (4.0%)	74 (11.9%)	<0.001
Frailty	116 (18.0%)	118 (12.5%)	418 (67.3%)	<0.001
Dialysis	15 (2.3%)	18 (1.9%)	9 (1.5%)	0.521
Logistic EuroSCORE	10.5 (6.5; 16.4)	10.4 (6.2; 19.5)	3.9 (3.4; 4.5)	0.007
CHADS2 score	2 (2; 3)	2 (2; 3)	2 (1; 3)	0.004
CHADS2Vasc score	4 (3; 5)	4 (3; 5)	4 (3; 4)	0.443

*descriptive statistics are based on count (%) or median (1st quartile; 3rd quartile), whereas inferential statistics are based on Fisher exact or Kruskal-Wallis tests; MR=mitral regurgitation.

Other significant differences were found for left ventricular dimensions and function, and mitral valve tenting area (Table 2), disfavoring less busy centers (all $p < 0.05$), and for left atrial dimensions, mitral valve calcification, mitral valve prolapse, tricuspid regurgitation severity, concomitant ECG abnormalities, and prevalence of atrial fibrillation, disfavoring higher volume institutions (all $p < 0.05$).

Table 2. Baseline imaging and ECG features according to tertiles of monthly volume, center-wise.*.

Feature	First tertile	Second tertile	Third tertile	P
Patients	645	947	621	-
LA AP diameter (mm)	45 (40; 50)	49 (44; 55)	49 (45; 55)	0.089
LV EDD (mm)	61 (54; 68)	58 (52; 64)	58 (50; 65)	<0.001
LV ESD (mm)	49 (38; 56)	41 (33; 51)	45 (35; 54)	<0.001
LV EDV (mL)	164 (120; 212)	137 (105; 181)	140 (100; 189)	<0.001
LV ESV (mL)	97 (55; 146)	73 (48; 116)	81 (47; 130)	<0.001
LVEF (%)	38 (30; 55)	42 (31; 55)	40 (30; 57)	0.008
Tenting area (cm ²)	3.0 (2.2; 3.7)	2.3 (1.6; 3.0)	1.9 (1.3; 2.4)	<0.001
Mean mitral valve gradient (mm Hg)	2 (1; 3)	2 (1; 2)	2 (2; 3)	0.148
Severe mitral regurgitation	495 (76.7%)	739 (78.0%)	493 (79.4%)	0.525
Severe mitral calcification	22 (3.4%)	28 (3.0%)	55 (8.9%)	<0.001
Mitral valve prolapse	163 (25.3%)	262 (27.7%)	205 (33.0%)	0.007
Flail leaflet	132 (20.5%)	176 (18.6%)	146 (23.5%)	0.063
Tricuspid regurgitation				<0.001
None or trace	23 (3.6%)	62 (6.6%)	22 (3.5%)	
Mild	282 (43.7%)	324 (34.2%)	234 (37.7%)	
Moderate	273 (42.3%)	458 (48.4%)	239 (38.5%)	
Severe	67 (10.4%)	103 (10.9%)	126 (20.3%)	
Systolic pulmonary artery pressure (mm Hg)	46 (40; 55)	45 (37; 55)	45 (35; 55)	0.071
Any ECG abnormality	152 (23.6%)	163 (17.2%)	296 (47.7%)	<0.001
Second-degree atrioventricular block	1 (0.2%)	0	3 (0.5%)	0.039
Third-degree atrioventricular block	1 (0.2%)	4 (0.4%)	2 (0.3%)	0.806
Right bundle branch block	17 (2.6%)	20 (2.1%)	18 (2.9%)	0.577
Left bundle branch block	27 (4.2%)	27 (2.9%)	28 (4.5%)	0.165
Atrial fibrillation	111 (17.2%)	118 (12.5%)	248 (39.9%)	<0.001
Coronary angiography performed	315 (48.8%)	223 (23.6%)	430 (69.2%)	<0.001
Coronary artery disease				0.711
No	201 (63.8%)	134 (60.1%)	275 (64.0%)	
1-vessel disease	49 (15.6%)	42 (18.8%)	67 (15.6%)	
2-vessel disease	25 (7.9%)	23 (10.3%)	48 (11.2%)	

3-vessel disease	22 (7.0%)	13 (5.8%)	22 (5.1%)	
Left main disease	18 (5.7%)	11 (4.9%)	18 (4.2%)	

*descriptive statistics are based on count (%) or median (1st quartile; 3rd quartile), whereas inferential statistics are based on Fisher exact or Kruskal-Wallis tests; AP=antero-posterior; EDD=end-diastolic diameter; EDV=end-diastolic volume; ESD=end-systolic diameter; ESV=end-systolic volume; LA=left atrium; LV=left ventricle; LVEF=left ventricular ejection fraction.

In terms of procedural details, significant differences were found in rates of implantation of multiple MitraClips, type of MitraClips used, device time, and fluoroscopy time (all $p < 0.05$; Table 3). Notably, device success rates were similar across tertiles, but procedural success marginally albeit significantly higher in busier centers ($p < 0.001$), with concomitantly lower rates of severe residual mitral regurgitation ($p = 0.001$). Patients in high-volume centers experienced fewer in-hospital bleeding events ($p = 0.006$) but more vascular complications ($p = 0.008$), without significant differences in in-hospital mortality ($p = 0.123$). Length of hospital stay was significantly shorter in higher-volume centers ($p < 0.001$).

Table 3. Procedural and in-hospital outcomes according to tertiles of monthly volume, center-wise.

Outcome	First tertile	Second tertile	Third tertile	P
Patients	645	947	621	
Implantation of ≥ 2 MitraClip devices	421 (65.3%)	508 (53.6%)	377 (60.7%)	< 0.001
Implantation on NT device	433 (67.1%)	499 (52.7%)	308 (49.6%)	< 0.001
Implantation on NTr device	98 (15.2%)	178 (18.8%)	92 (14.8%)	0.062
Implantation of XTr device	160 (24.8%)	358 (37.8%)	249 (40.1%)	< 0.001
Device time (minutes)	2.3 (1.5; 3.5)	2.1 (1.5; 2.7)	3.5 (2.1; 4.4)	< 0.001
Fluoroscopy time (minutes)	0.8 (0.6; 1.7)	1.3 (0.8; 1.9)	0.4 (0.2; 0.8)	< 0.001
Device success	641 (99.4%)	942 (99.5%)	620 (99.8%)	0.513
Procedural success	600 (93.0%)	926 (97.8%)	593 (95.5%)	< 0.001
Procedural death	3 (0.5%)	0	2 (0.3%)	0.104
Mitral valve gradient at end of procedure	3 (2; 4)	3 (2; 4)	3 (3; 5)	< 0.001
Mitral regurgitation at end of procedure				< 0.001
None	386 (59.8%)	561 (59.2%)	453 (73.0%)	
Mild	209 (32.4%)	348 (36.8%)	147 (23.7%)	
Moderate	34 (5.3%)	26 (2.8%)	12 (1.9%)	
Severe	16 (2.5%)	12 (1.3%)	9 (1.5%)	
Inhospital death	18 (2.8%)	20 (2.1%)	24 (3.9%)	0.123
Inhospital stroke	0	0	0	-
Inhospital bleeding				0.006
None	644 (99.8%)	939 (99.2%)	610 (98.2%)	
Minor	0	5 (0.5%)	7 (1.1%)	
Major	0	1 (0.1%)	4 (0.6%)	
Disabling	1 (0.2%)	2 (0.2%)	0	

Inhospital vascular complication	1 (0.2%)	5 (0.5%)	10 (1.6%)	0.008
Days of hospitalization	8 (5; 12)	5 (4; 8)	5 (4; 8)	<0.001
Mitral regurgitation at discharge				0.001
None	347 (55.3%)	503 (54.3%)	388 (65.0%)	
Mild	226 (36.0%)	354 (38.2%)	171 (28.6%)	
Moderate	39 (6.2%)	59 (6.4%)	27 (4.5%)	
Severe	15 (2.4%)	11 (1.2%)	11 (1.0%)	
Systolic pulmonary artery pressure (mm Hg)	40 (32; 46)	40 (35; 50)	40 (30; 45)	<0.001

During a median follow-up of 14 months, details on a total of 539 (24.4%) deaths, 286 (12.9%) cardiac deaths, 685 (31.0%) deaths or hospitalizations, and 359 (16.2%) cardiac deaths or hospitalizations for heart failure were accrued (Table 4). Moderate or severe mitral regurgitation was reported overall in 308 (14.3%). Survival analysis was performed using first unadjusted models (Table 5), and these suggested worse outcomes in less busy centers for death, cardiac death, the composite of death or hospitalization, and the composite of cardiac death or hospitalization for heart failure (all $p < 0.05$). However, after taking into account potential confounders, all these differences were no longer significant, except for cardiac death or hospitalization for heart failure, which appeared significantly less common in busiest centers (all $p < 0.05$; Figure 1).

Table 4. Cumulative outcomes at follow-up according to tertiles of monthly volume, center-wise.

Outcome	First tertile	Second tertile	Third tertile	P
Patients	645	947	621	
Follow-up (months)	12 (1; 24)	21 (10; 36)	13 (1; 25)	<0.001
Death	152 (23.6%)	251 (26.5%)	136 (21.9%)	0.101
Cardiac death	86 (13.3%)	125 (13.2%)	75 (12.1%)	0.764
Hospitalization	107 (16.6%)	114 (12.0%)	68 (11.0%)	0.007
Hospitalization for heart failure	82 (12.7%)	86 (9.1%)	65 (10.5%)	0.070
Death or hospitalization	199 (30.1%)	307 (32.4%)	179 (28.8%)	0.323
Cardiac death or hospitalization for heart failure	142 (22.0%)	189 (20.0%)	127 (20.5%)	0.596
Mitral valve surgery	4 (0.6%)	8 (0.8%)	13 (2.1%)	0.034
Cerebrovascular accident	12 (1.9%)	13 (1.4%)	9 (1.5%)	0.722
New York Heart Association				0.006
I	59 (14.0%)	159 (21.3%)	55 (13.3%)	
I	270 (64.0%)	425 (56.9%)	254 (61.2%)	
III	85 (20.1%)	153 (20.5%)	98 (23.6%)	
IV	8 (1.9%)	10 (1.3%)	8 (1.9%)	
Atrial fibrillation	124 (19.2%)	135 (14.3%)	258 (41.6%)	<0.001
End-diastolic diameter (mm)	60 (53; 67)	57 (50; 64)	56 (49; 62)	<0.001
End-systolic diameter (mm)	48 (38; 56)	40 (31; 50)	40 (35; 53)	<0.001
End-diastolic volume (mL)	159 (120; 220)	131 (100; 180)	133 (98; 187)	<0.001
End-systolic volume (mL)	90 (56; 138)	73 (45; 115)	85 (45; 130)	0.004

Left ventricular ejection fraction (%)	38 (28; 51)	42 (30; 55)	38 (27; 52)	<0.001
Mitral valve gradient (mm Hg)	3 (3; 5)	4 (3; 5)	4 (3; 5)	0.023
Mitral regurgitation				0.113
None	281 (44.7%)	433 (46.7%)	297 (49.8%)	
Mild	250 (39.8%)	365 (39.4%)	219 (36.7%)	
Moderate	66 (10.5%)	103 (11.1%)	53 (8.9%)	
Severe	32 (5.1%)	26 (2.8%)	28 (4.7%)	
Angiotensin receptor blockers	219 (52.4%)	246 (33.1%)	85 (22.3%)	<0.001
Calcium channel antagonists	34 (8.1%)	77 (10.4%)	41 (10.8%)	0.367
Betablockers	348 (82.7%)	362 (75.4%)	299 (78.3%)	0.015
Ivabradine	23 (5.5%)	30 (4.0%)	18 (4.7%)	0.495
Furosemide	393 (92.7%)	677 (90.6%)	361 (90.5%)	0.421
Aspirin	185 (44.2%)	318 (42.5%)	183 (48.3%)	0.183
Thienopyridines	64 (15.4%)	161 (21.6%)	89 (23.5%)	<0.001
Novel oral anticoagulants	154 (24.8%)	262 (28.6%)	113 (18.7%)	<0.001
Warfarin	167 (26.9%)	221 (24.2%)	148 (24.6%)	0.455
Intravenous inotropes	11 (2.6%)	3 (0.4%)	6 (1.6%)	0.003

Table 5. Unadjusted and adjusted survival analysis according to tertiles of monthly volume, center-wise.*.

Outcome	Unadjusted effect estimates	Adjusted effect estimates
Death		
Tertile 2 vs 1	0.78 (0.64-0.96), p=0.018	0.60 (0.19-1.82), p=0.364
Tertile 3 vs 1	0.90 (0.71-1.13), p=0.365	0.54 (0.16-1.78), p=0.308
Tertile 3 vs 2	1.28 (0.93-1.42), p=0.191	0.90 (0.36-2.21), p=0.814
Cardiac death		
Tertile 2 vs 1	0.70 (0.53-0.93), p=0.015	0.55 (0.14-2.21), p=0.398
Tertile 3 vs 1	0.89 (0.65-1.21), p=0.456	0.44 (0.09-2.12), p=0.304
Tertile 3 vs 2	1.26 (0.94-1.69), p=0.117	0.80 (0.24-2.68), p=0.713
Death or hospitalization		
Tertile 2 vs 1	0.80 (0.67-0.96), p=0.014	0.63 (0.24-1.66), p=0.351
Tertile 3 vs 1	0.89 (0.72-1.09), p=0.246	0.37 (0.13-1.07), p=0.065
Tertile 3 vs 2	1.11 (0.92-1.34), p=0.265	0.59 (0.25-1.36), p=0.213
Cardiac death or hospitalization for heart failure		
Tertile 2 vs 1	0.64 (0.50-0.82), p<0.001	0.62 (0.16-2.37), p=0.488
Tertile 3 vs 1	0.83 (0.64-1.09), p<0.001	0.16 (0.03-0.81), p=0.026
Tertile 3 vs 2	1.30 (1.01-1.69), p=0.045	0.26 (0.07-0.99), p=0.048

*reported as hazard ratio (95% confidence interval), p value.




Figure 1. Hazard ratios (95% confidence intervals) at unadjusted and adjusted Cox proportional hazard analysis comparing different tertiles (T) of monthly volume, center-wise. HF=heart failure; Hosp=hospitalization.

Similar trends were observed when leveraging tertiles of overall center volume and when comparing for each center the first 50 cases with the following ones (Tables S1–S4), with higher procedural success rates in busier/more experienced centers, and similarly trends favoring them for long-term clinical outcomes.

Discussion

High institutional monthly volume in TEER mitral valve repair appear to correlate with improved procedural success rate and shorter hospitalizations. Similarly favorable results were found for long-term rates of cardiac death or hospitalization for heart failure.

The evidence base appraising the impact of institutional volume and expertise on TEER outcomes is complex and heterogeneous, but some studies have indeed suggested that some thresholds are important to achieve satisfactory procedural, in-hospital and mid-term outcomes (Table S5) (12,14,16-18,21). The findings from the present GIOTTO-VAT study support the concept that institutional volume in TEER may significantly impact on clinical outcomes. Notably, centers with higher monthly case volumes demonstrated greater procedural success. Furthermore, similarly favorable results were evident for long-term outcomes at unadjusted and adjusted analysis. These results align with existing evidence in the field of structural heart interventions, where operator and institutional experience have been shown to positively impact clinical outcomes.(12-13)

Interestingly, while higher-volume centers showed better procedural metrics, long-term clinical outcomes, including mortality, were comparable across tertiles. This suggests that while experience improves technical execution and immediate safety, patient selection and underlying clinical conditions remain key determinants of long-term prognosis. Moreover, the impact of experienced proctors affiliated at high volume centers providing careful guidance to lower volume institutions cannot be discounted, in person or remotely.(22) Indeed, the impact of proctors should be carefully

appraised in future studies, together with detailed analyses on post-procedural care and management protocols.

A notable finding was the reduced hospitalization duration in high-volume centers compared to lower-volume ones. This may reflect more efficient perioperative management, shorter procedural times, and faster post-operative recovery.⁽²³⁾ Shorter hospital stays can also reduce healthcare costs, which is a significant consideration in the growing adoption of TEER for mitral regurgitation management, thus reinforcing the call for established expertise in all phases of management of patients with significant mitral regurgitation.⁽²⁴⁾

Despite some clear hints that higher volumes over time are associated with better outcomes in patients undergoing TEER for significant mitral regurgitation, results were not altogether consistent. In addition, even adjusted analyses cannot be considered devoid of risk of residual confounding. Furthermore, the risk of duplicity and type I error inflation due to a plethora of statistical tests remains substantial, and thus external replication of the present findings is paramount.

In conclusion, the present GIOTTO-VAT study suggests that hospitals with a higher volume of cases over time may yield improved procedural success rates, with ensuing shorter hospitalizations. Long-term rates of cardiac death or hospitalization for heart failure also favored centers with higher case/month figures. These findings inform on the importance of operator experience and center expertise to achieve state-of-the-art results with TEER, while confirming the usefulness of the proctoring approach when naïve centers begin a TEER program.

Funding: The GIOTTO (GIse registry Of Transcatheter treatment of mitral valve regurgitaTiOn) registry is sponsored by the Italian Society of Invasive Cardiology, with an unrestricted grant by Abbott Vascular, Santa Clara, CA, USA.

Disclosure: Giuseppe Biondi-Zoccai has consulted for Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina, outside the present work. All other authors report no conflict of interest.

References

1. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghini C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med* 2011;364:1395-406.
2. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ; COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N Engl J Med* 2018;379:2307-2318.
3. Zhou S, Egorova N, Moskowitz G, Giustino G, Ailawadi G, Acker MA, Gillinov M, Moskowitz A, Gelijns A. Trends in MitraClip, mitral valve repair, and mitral valve replacement from 2000 to 2016. *J Thorac Cardiovasc Surg* 2021;162:551-562.e4.
4. Shi W, Zhang W, Zhang D, Ye G, Ding C. Mortality and Clinical Predictors After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. *Front Cardiovasc Med* 2022;9:918712.
5. Bedogni F, Testa L, Rubbio AP, Bianchi G, Grasso C, Scandura S, De Marco F, Tusa M, Denti P, Alfieri O, Giordano A, Ferraro P, Bartorelli AL, Mongiardo A, Petronio AS, Giannini C, De Felice F, Baldi C, Castriota F, Adamo M, Masiero G, Godino C, Montorfano M, Tarantini G, Tamburino C. Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). *Cardiovasc Revasc Med* 2020;21:1057-1062.
6. Salvatore T, Ricci F, Dangas GD, Rana BS, Ceriello L, Testa L, Khanji MY, Caterino AL, Fiore C, Popolo Rubbio A, Appignani M, Di Fulvio M, Bedogni F, Gallina S, Zimarino M. Selection of the Optimal Candidate to MitraClip for Secondary Mitral Regurgitation: Beyond Mitral Valve Morphology. *Front Cardiovasc Med* 2021;8:585415.

7. Giordano A, Biondi-Zoccai G, Finizio F, Ferraro P, Denti P, Rubbio AP, Petronio AS, Bartorelli AL, Mongiardo A, De Felice F, Adamo M, Montorfano M, Baldi C, Tarantini G, Giannini F, Ronco F, Monteforte I, Villa E, Ferrario M, Fiocca L, Castriota F, Tamburino C. Characteristics and outcomes of MitraClip in octogenarians: Evidence from 1853 patients in the GIOTTO registry. *Int J Cardiol* 2021;342:65-71.
8. Giordano A, Ferraro P, Finizio F, Biondi-Zoccai G, Denti P, Bedogni F, Rubbio AP, Petronio AS, Bartorelli AL, Mongiardo A, Giordano S, De Felice F, Adamo M, Montorfano M, Baldi C, Tarantini G, Giannini F, Ronco F, Monteforte I, Villa E, Ferrario M, Fiocca L, Castriota F, Tamburino C. Implantation of one, two or multiple MitraClip™ for transcatheter mitral valve repair: insights from a 1824-patient multicenter study. *Panminerva Med* 2022;64:1-8.
9. Giordano A, Ferraro P, Finizio F, Cimmino M, Albanese M, Morello A, Biondi-Zoccai G, Denti P, Rubbio AP, Bedogni F, Bartorelli AL, Mongiardo A, Giordano S, De Felice F, Adamo M, Montorfano M, Maisano F, Tarantini G, Giannini F, Ronco F, Villa E, Ferrario M, Fiocca L, Castriota F, Squeri A, Pepe M, Tamburino C, Corcione N. Incidence and Predictors of Cerebrovascular Accidents in Patients Undergoing Transcatheter Mitral Valve Repair with Mitraclip. *Am J Cardiol* 2024 Aug 1:S0002-9149(24)00575-7. doi: 10.1016/j.amjcard.2024.07.037. Epub ahead of print.
10. Giordano A, Ferraro P, Finizio F, Corcione N, Cimmino M, Biondi-Zoccai G, Denti P, Rubbio AP, Petronio AS, Bartorelli AL, Mongiardo A, Giordano S, De Felice F, Adamo M, Montorfano M, Baldi C, Tarantini G, Giannini F, Ronco F, Monteforte I, Villa E, Ferrario M, Fiocca L, Castriota F, Squeri A, Tamburino C, Bedogni F. Transcatheter Mitral Valve Repair With the MitraClip Device for Prior Mitral Valve Repair Failure: Insights From the GIOTTO-FAILS Study. *J Am Heart Assoc* 2024;13:e033605.
11. Giordano A, Pepe M, Biondi-Zoccai G, Corcione N, Finizio F, Ferraro P, Denti P, Popolo Rubbio A, Petronio S, Bartorelli AL, Nestola PL, Mongiardo A, De Felice F, Adamo M, Montorfano M, Baldi C, Tarantini G, Giannini F, Ronco F, Monteforte I, Villa E, Ferrario Ormezzano M, Fiocca L, Castriota F, Bedogni F, Tamburino C. Impact of coronary artery disease on outcome after transcatheter edge-to-edge mitral valve repair with the MitraClip system. *Panminerva Med* 2023;65:443-453.
12. Chhatrwalla AK, Vemulapalli S, Holmes DR Jr, Dai D, Li Z, Ailawadi G, Glower D, Kar S, Mack MJ, Rymer J, Kosinski AS, Sorajja P. Institutional Experience With Transcatheter Mitral Valve Repair and Clinical Outcomes: Insights From the TVT Registry. *JACC Cardiovasc Interv* 2019;12:1342-1352.
13. Chhatrwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, Mack MJ, Ailawadi G, Rymer J, Manandhar P, Kosinski AS, Sorajja P. Operator Experience and Outcomes of Transcatheter Mitral Valve Repair in the United States. *J Am Coll Cardiol* 2019;74:2955-2965.
14. Bonow RO, O'Gara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, Hung JW, Lindenfeld J, Morris A, Satpathy R, Whisenant B, Woo YJ. 2019 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Mitral Valve Intervention: A Joint Report of the American Association for Thoracic Surgery, the American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons. *J Am Coll Cardiol* 2020;76:96-117.
15. Basso C, Musumeci G, Saia F, Tarantini F. Percutaneous approaches to mitral valve disease. Torino, 2019: Minerva Medica.
16. Kolte D, Butala NM, Kennedy KF, Wasfy JH, Jena AB, Sakhuja R, Langer N, Melnitchouk S, Sundt TM 3rd, Passeri JJ, Palacios IF, Inglessis I, Elmariah S. Association Between Hospital Cardiovascular Procedural Volumes and Transcatheter Mitral Valve Repair Outcomes. *Cardiovasc Revasc Med* 2022;36:27-33.
17. Keller K, Hobohm L, Schmidtmann I, Münzel T, Baldus S, von Bardeleben RS. Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip® in Germany. *Eur J Heart Fail* 2021;23(8):1380-1389.
18. Shoji S, Kuno T, Malik A, Briasoulis A, Inohara T, Kampaktsis PN, Kohsaka S, Latib A. Association between institutional volume of transcatheter mitral valve repair and readmission rates: A report from the Nationwide Readmission Database. *Int J Cardiol* 2023;383:70-74.
19. Corcione N, Ferraro P, Finizio F, Cimmino M, Albanese M, Morello A, Biondi-Zoccai G, Denti P, Popolo Rubbio A, Bedogni F, Bartorelli AL, Mongiardo A, Giordano S, De Felice F, Adamo M, Montorfano M, Maisano F, Tarantini G, Giannini F, Ronco F, Villa E, Ferrario M, Fiocca L, Castriota F, Squeri A, Pepe M,

- Tamburino C, Giordano A. Overall impact of tethering and of its symmetric and asymmetric subtypes on early and long-term outcome of transcatheter edge-to-edge repair of significant mitral valve regurgitation. *Int J Cardiol* 2024;421:132874.
20. Corcione N, Ferraro P, Morello A, Cimmino M, Albanese M, Avellino R, Turino S, Polimeno M, Messina S, Maresca G, Giordano S, Biondi-Zoccai G, Pepe M, Giordano A. A 25-year-long journey into interventional cardiology: looking back, and rushing forward. *Minerva Med* 2024;115:465-475.
 21. Bansal K, Pawar S, Gupta T, Gilani F, Khera S, Kolte D. Association Between Hospital Volume and 30-Day Readmissions After Transcatheter Mitral Valve Edge-to-Edge Repair. *Am J Cardiol* 2023;203:149-156.
 22. Ascione G, Rossini G, Schiavi D, Azzola Guicciardi N, Saccocci M, Buzzatti N, Godino C, Alfieri O, Agricola E, Maisano F, Denti P. Remote proctoring during structural heart procedures: Toward a widespread diffusion of knowledge using mixed reality. *Catheter Cardiovasc Interv.*2024;104:1037-1043.
 23. Nita N, Schneider L, Dahme T, Markovic S, Keßler M, Rottbauer W, Tadic M. Trends in Transcatheter Edge-to-Edge Mitral Valve Repair Over a Decade: Data From the MiTra ULM Registry. *Front Cardiovasc Med* 2022;9:850356.
 24. Stone GW. Volume-Outcome Relationships for Transcatheter Mitral Valve Repair: More Is Better. *JACC Cardiovasc Interv* 2019;12:1353-1355.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.